Zymeworks Inc.
ZYME · Nasdaq · USD · Market cap $1.8B · 243 employees
Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases.
FAIL · Does not pass the screenPrice as of 20 Nov 2026Daily close, not a live quote
Screened 2026-11-20 · the tape above runs as of 14:15 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price26.14 USD at the 20 Nov 2026 close
- Our value readFair vs our fair value, as of 20 Nov 2026
- Our regime readMarkup, as of 15 Nov 2026
- Ethical screenDoes not pass
- OptionsOpen interest leans heavily to calls (put/call 0.42)
- Last reviewed20 Nov 2026 (1 day ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
Our fair-value range: $24.01 to $27.62, base estimate $24.01 (screen dated 2026-11-20).
- Trend Markup
- Insiders insiders sold, $357,557, latest filing 2026-10-09
- Positioning no disclosures inside 60 days, left as found
- Options put/call open interest 0.42, read 2026-11-19
- Ethical does not pass the values gate
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
This name holds its markup label.
Zymeworks Inc. holds its Markup at $26.14. The statistical read favours the sellers, held for 4 days.
| Phase | Markup |
| Quantitative state | The statistical read favours the sellers, held for 4 days |
| Price at the screen | $26.14 |
| Valuation | 48.75 trailing · 87.10 forward price to earnings |
| Values screen | FAIL · score 70.0 |
| Beta | 1.30 |
Five Screens: ZYME's Results
FAIL. Interest-bearing securities
| Test | Figure | Limit | Status |
|---|---|---|---|
| Business activity | Permissible | Permissible core business | Pass |
| Debt load | 5.27% | Below 33% | Pass |
| Interest-bearing cash | 54.15% | Below 33% | Fail |
| Receivables | 13.22% | Below 49% | Pass |
| Revenue purity | 12.60% | Below 5% | Fail |
Definitions, sources and threshold rules: ticker values-screen methodology.
The Ethical ReadWhy It Falls Short, in Plain English
Zymeworks's business is fine, but its cash and interest-bearing securities are about 54% of its assets, well over the ~33% line, so it does not pass on the financial screens.
Read as at 20 Nov 2026. It updates when the underlying figures move, and past reads are kept below. How we screen.
Follow this verdict
Get an email when ZYME's ethical verdict changes
Today ZYME does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
The Fair Value Range
Our analysis reads Fair to fair value, as of 20 Nov 2026: it trades above our $24.01 fair value estimate, 828.70% revenue growth.
USD, 2026-11-20 screen. The price runs 8.9% over base.
Street: 14 covering, consensus Strong Buy. Average target +59%.
Biotech Pipeline Hits Revenue Freefall Wall
Picture a lab racing to craft the next cancer fighter while the cash register rings up losses instead of sales. Zymeworks builds antibody platforms for tough diseases yet just posted revenue growth of minus 91 percent and a profit margin of minus 126 percent. At 24 dollars against our fair value of 20 dollars the shares already price in miracles that the current numbers do not support.
We pass because the opportunity rating is none. Forward earnings sit at 85 times while return on equity runs at minus 42 percent and the moat stays unknown. Analyst targets cluster near 37 dollars but that optimism collides with an 18 percent negative margin of safety and a business still burning cash at scale.
The ethical screen clears yet the financial picture flags classic early stage biotech hazards: binary trial outcomes, dilution risk and the chance peak losses arrive before any durable product. Numbers this weak usually warn of further downside rather than hidden upside. Analysis, not advice.
| Forward P/E | 87.1xcheap for a company growing this fast |
| Trailing P/E | 48.8xexpensive: the price assumes strong growth ahead |
| EPS, trailing | 0.53 |
| EPS, forward | 0.30 |
| Revenue growth | +828.7%growing very fast |
| Profit margin | 16.3%healthy profit margins |
| Return on equity | 15.0%a solid return on shareholder capital |
| FCF yield | -10.80% |
| Debt to equity | 0.21minimal debt: a conservative balance sheet |
| Current ratio | 3.30comfortably covers its short-term bills |
| Beta | 1.30moves a little more than the market |
| Short interest, float | 0.13% |
| 52-week range | 21.52 - 31.97 |
| Market cap | $1.8B |
| Employees | 243 |
ZYME-specific watchpoints · The things to watch: it's a small-cap, so the share price can swing harder than the market; it already moves more than the market on an average day; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Metric definitions and interpretation rules: ticker-page methodology.
Every Entry, As Written
The framework has shifted from accumulation to markup since the last review.
The framework has shifted from markup to accumulation since the last review.
Earnings landed in this window. Ethical screening: FAIL.
Written on its date, before the outcome; never pruned.
- Milestone Payment Lifts Zymeworks Stock Outlook After Profitable Quarter Yahoo Finance · 9d ago
- Zymeworks Inc. (ZYME) Misses Q3 Earnings Estimates Yahoo Finance · 12d ago
- Zymeworks Provides Corporate Update and Reports Third Quarter 2026 Financial Results Yahoo Finance · 12d ago
- Zymeworks (ZYME) Stock May Be Overvalued On Its New Lung Cancer Deal Yahoo Finance · 17d ago
- Zymeworks (ZYME) Gains Fresh Backing On Trial Data And Roche Deal Yahoo Finance · 17d ago
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
Screened names in the same industry · explore each on its own page.
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-09 | Schayowitz Adam | EVP, Head of R, D | S - Sale+OE | 13,832 | $357,557 |
Public filings, recorded as found. The full tape lives at Insider Intelligence.
| Date | Politician | Party | Type | Amount |
|---|---|---|---|---|
| 2026-09-29 | Gil Cisneros | Democrat | sell | 1K–15K |
| 2026-09-29 | Gil Cisneros | Democrat | sell | 1K–15K |
| 2026-09-29 | Gil Cisneros | Democrat | sell | 1K–15K |
| 2026-09-29 | Gil Cisneros | Democrat | sell | 1K–15K |
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $24.03 | -4.9% | · | $951 | -4.9% |
| 2 months | $26.32 | -13.2% | · | $868 | -13.2% |
| 3 months | $23.23 | -1.6% | · | $984 | -1.6% |
| 6 months | $24.94 | -8.4% | · | $916 | -8.4% |
| 1 year | $13.07 | +74.8% | · | $1,748 | +74.8% |
| 2 years | $8.97 | +154.7% | · | $2,547 | +154.7% |
| 3 years | $8.52 | +168.2% | · | $2,682 | +168.2% |
| 5 years | $37.73 | -39.4% | · | $606 | -39.4% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever ZYME does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.